Maxim Group analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals (NYSE: INO) and doubled his price target from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE